Familial Hypercholesterolemia

Metabolic·MeSH: Hyperlipoproteinemia Type II

Prevalence

0.5 / 100K

19 drugs in development·12 companies·7 clinical trials

Drug Pipeline by Phase

Approved(3)

Drug	Company
colesevelam	Impax Laboratories, LLC (IPXL)
Evkeeza	Ultragenyx Pharmaceutical Inc. (RARE)
pitavastatin	Mylan II B.V. (MYL)

Phase 3(6)

Drug	Company
Enlicitide Decanoate	Merck & Co., Inc. (MRK)
Evinacumab	Ultragenyx Pharmaceutical Inc. (RARE)
inclisiran	MEDICINES CO /DE (MDCO)
inclisiran sodium 300 mg in	Novartis AG (NVS)
syh2053	NYMOX PHARMACEUTICAL CORP (NYMXF)
Zodasiran	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Phase 2(3)

Drug	Company
aro-ang 3	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
inclisiran	Novartis AG (NVS)
mgl-3196	MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Phase 1(5)

Drug	Company
aem-28	Capstone Holding Corp. (CAPS)
verve-101	Verve Therapeutics, Inc. (VERV)
verve-102	Verve Therapeutics, Inc. (VERV)
VERVE-102	Travere Therapeutics, Inc. (TVTX)
verve-301	Verve Therapeutics, Inc. (VERV)

Preclinical(1)

Drug	Company
aem-28-08	Capstone Holding Corp. (CAPS)

Phase 4(1)

Drug	Company
Inclisiran	Novartis AG (NVS)

BioSniper tracks 19 drugs in development for Familial Hypercholesterolemia across 12 companies.

There are 7 clinical trials targeting Familial Hypercholesterolemia tracked by BioSniper.

The estimated prevalence of Familial Hypercholesterolemia is approximately 0.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.